Navigation Links
Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc.
Date:1/15/2014

DUBLIN, January 15, 2014 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it has waived the Office of Fair Trading (OFT) approval condition to the announced tender offer for all of the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).  

As a result of the waiver, the transaction is no longer conditional on OFT approval, and Shire expects to complete the tender offer on January 24, 2014 following the currently scheduled expiration time, subject to the satisfaction of all of the remaining conditions to the tender offer.  The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) expired on December 10, 2013.  

The tender offer is scheduled to expire at midnight, New York City time, on Thursday, January 23, 2014 (one minute after 11:59 p.m., New York City time, on January 23, 2014).

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

http://www.shire.com


ADDITIONAL INFORMATION AND WHERE TO FIND IT  

This announcement is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell ViroPharma common stock. The offer to buy ViroPharma common stock is being made pursuant to a tender offer statement (including the offer to purchase, letter of transmittal and other related t
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Receives Two Preclinical Milestone Payments Under Collaboration With Shire
2. Shire Extends Tender Offer for ViroPharma
3. Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Use of Lifitegrast (5.0% Ophthalmic Solution) in Adults With Dry Eye Disease
4. MinuteClinic Opens First Clinic Locations in New Hampshire
5. Block & Leviton LLP Investigates ViroPharma Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Shire PLC.
6. Shire to Present at the Bank of America Merrill Lynch Global Health Care Conference
7. Shire to Present at the Morgan Stanley Global Healthcare Conference
8. Shire Reports 7% Product Sales Growth: Anticipating Double Digit Non GAAP Earnings Growth in 2013
9. Shire Announces Award Recipients for 2013 US ADHD Scholarship Program
10. Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
11. SARcode Bioscience Announces Acquisition by Shire US Holdings Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...   Physicians Rx Pharmacy ("PRxP") today announced ... organization as President and Chief Executive Officer.  ... Chief Executive Officer for Soleo Health Specialty Infusion Services, ... Rx Pharmacy, be responsible for leading the rapidly-growing 340B ... to bring Gaston on as the President and CEO ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and Markets ... "Inhaled Drug Delivery (London, UK - November 19-20, ... Inhaled Drug Delivery meeting will cover industry case studies, ... more. The Co-Chairmen are Dr Steven Nichols , ... Director, Mylan. Companies participating include: ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 Research ... "Pharmaceutical Regulatory Affairs in Latin America (London, UK - November 16-18, 2015)" ... Markets across Latin America including Columbia, ... , Argentina , Uruguay , ... , Central America , Chile ...
Breaking Medicine Technology:Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2
... Dec. 28, 2011 Reportlinker.com announces ... is available in its catalogue: ... Diabetes Care Devices Market Outlook to ... http://www.reportlinker.com/p0739469/South-and-Central-America-Diabetes-Care-Devices-Market-Outlook-to-2017--Glucose-Monitoring-and-Insulin-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ...
... 2011 BNA Books , a division of specialized ... publication of the 2011 Supplement to ... domestic and international developments in pharmaceutical patent law. ... Law, Second Edition  tracks legal developments within the PTO, the ...
Cached Medicine Technology:South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 2South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 3South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 4South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 5South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 6South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 7South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 8South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 9BNA Books Announces the Publication of the 2011 Supplement to "Pharmaceutical Patent Law, Second Edition" 2BNA Books Announces the Publication of the 2011 Supplement to "Pharmaceutical Patent Law, Second Edition" 3
(Date:9/2/2015)... , ... September 02, 2015 , ... Based in Beverly ... fleet of truly superb luxury vehicles based on which of the latest and greatest ... the latest step forward in pursuit of this goal: a 2015 Rolls Royce ...
(Date:9/2/2015)... DC (PRWEB) , ... September 02, 2015 , ... Telehealth ... American Well Corp., contracted to handle the telehealth services of more than 12 Blues ... Cross and Blue Shield Plans takes a look this growing trend, interviewing executives at ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... from the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham and ... gift comes six months after WCHN recruited nationally known gynecologic oncologist Thomas J. ...
(Date:9/2/2015)... Fort Lauderdale, FL (PRWEB) , ... September 02, ... ... cost for Amgen’s Blincyto® (blinatumomab) – in the news recently following a decision ... with hospitalized Medicare patients – is likely to average approximately $71,000 or roughly ...
(Date:9/2/2015)... Bryn Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Location: Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, ... justCommunity, Inc., will host a day-long seminar featuring New York Times best-selling author Sam ...
Breaking Medicine News(10 mins):Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2
... women,s risk gets even smaller 10 years after stopping ... News) -- Women taking oral contraceptives are at a ... decade after stopping the pill even this very small ... that finding doesn,t change the recommendation for women to ...
... year over year growth driven by Loestrin 24 and Taclonex; Company ... updates full year 2007 financial guidance, ST. ... today announced its results for the quarter ended,September 30, 2007. Revenue ... of 16.3%, over the prior year quarter. The,primary drivers of the ...
... Highlighted by Continued Momentum in Global Commercialization, Program for Once-Daily ... ... III Study -, LAVAL, QC, Nov. 9 /PRNewswire-FirstCall/ - ... the third quarter of fiscal,2007, ended September 30, 2007. All ...
... event in 2007, net loss stable ... otherwise noted), BELLEVILLE, ON, Nov. 9 /PRNewswire-FirstCall/ - ... company, today announced financial results for the first,quarter of ... "We are also focused on the successful completion of ...
... Pharmaceutical product teams,have the power to make ... The problem is,launch teams often lack the right ... only produce a sub-optimal launch. In fact, ... and cross-functional team work are key ingredients,during product ...
... Support Continued Advancement of Novel Technology and ... ... Inc., a,privately-held therapeutic antibody product company, today announced that,it has raised ... A/S.,Additional investors participating significantly in the round were Frazier,Healthcare Ventures and ...
Cached Medicine News:Health News:Pill Poses Little Cervical Cancer Risk 2Health News:Pill Poses Little Cervical Cancer Risk 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 14
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: